Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Gains from Sales and Divestitures (2016 - 2025)

Seres Therapeutics' Gains from Sales and Divestitures history spans 11 years, with the latest figure at $52160.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 96.29% year-over-year to $52160.0; the TTM value through Sep 2025 reached $52160.0, down 96.29%, while the annual FY2024 figure was $2.2 million, 44.01% up from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $52160.0 at Seres Therapeutics, up from $35161.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.2 million in Q4 2024 and bottomed at $650.0 in Q1 2021.
  • The 5-year median for Gains from Sales and Divestitures is $259023.0 (2023), against an average of $458550.1.
  • The largest annual shift saw Gains from Sales and Divestitures tumbled 99.48% in 2021 before it surged 19380.92% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $650.0 in 2021, then skyrocketed by 43346.31% to $282401.0 in 2022, then soared by 439.89% to $1.5 million in 2023, then skyrocketed by 44.01% to $2.2 million in 2024, then crashed by 97.62% to $52160.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Gains from Sales and Divestitures are $52160.0 (Q3 2025), $35161.0 (Q2 2025), and $12966.0 (Q1 2025).